- Home
- SPRO vs JMM Comparison
SPRO vs JMM Comparison
Compare SPRO & JMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- JMM
- Stock Information
- Founded
- SPRO 2013
- JMM 1988
- Country
- SPRO United States
- JMM United States
- Employees
- SPRO N/A
- JMM N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- JMM Trusts Except Educational Religious and Charitable
- Sector
- SPRO Health Care
- JMM Finance
- Exchange
- SPRO Nasdaq
- JMM Nasdaq
- Market Cap
- SPRO 62.7M
- JMM 57.1M
- IPO Year
- SPRO 2017
- JMM N/A
- Fundamental
- Price
- SPRO $1.17
- JMM $6.04
- Analyst Decision
- SPRO Buy
- JMM
- Analyst Count
- SPRO 3
- JMM 0
- Target Price
- SPRO $5.00
- JMM N/A
- AVG Volume (30 Days)
- SPRO 470.6K
- JMM 16.1K
- Earning Date
- SPRO 11-14-2024
- JMM 01-01-0001
- Dividend Yield
- SPRO N/A
- JMM 5.44%
- EPS Growth
- SPRO N/A
- JMM N/A
- EPS
- SPRO 0.06
- JMM N/A
- Revenue
- SPRO $106,455,000.00
- JMM N/A
- Revenue This Year
- SPRO N/A
- JMM N/A
- Revenue Next Year
- SPRO N/A
- JMM N/A
- P/E Ratio
- SPRO $17.92
- JMM N/A
- Revenue Growth
- SPRO 37.01
- JMM N/A
- 52 Week Low
- SPRO $1.01
- JMM $5.29
- 52 Week High
- SPRO $1.89
- JMM $6.10
- Technical
- Relative Strength Index (RSI)
- SPRO 41.49
- JMM 45.39
- Support Level
- SPRO $1.28
- JMM $5.98
- Resistance Level
- SPRO $1.22
- JMM $6.09
- Average True Range (ATR)
- SPRO 0.07
- JMM 0.05
- MACD
- SPRO -0.01
- JMM 0.00
- Stochastic Oscillator
- SPRO 32.73
- JMM 40.91
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About JMM Nuveen Multi-Market Income Fund (MA)
Nuveen Multi-Market Income Fund is a United States-based closed-end management investment company. The investment objective of the company is to provide high monthly income consistent with prudent risk to capital. The fund seeks to invest in debt securities, including, but not limited to, U.S. agency and privately issued mortgage-backed securities, corporate debt securities, and asset-backed securities.